

CHALLENGE: REGS AND TECH

Developing an **AI/ML and hardware healthcare solution** requires balancing regulatory requirements, scientific problems and business needs.

Our whole-biotech expertise in **R&D, cloud, clinical trials, hiring and delivery** to validate and prioritise business decisions.

A Wardley map with an **initial software design** were produced to give the team the best possible touchstone resource for decision making.

Can Sense

Delivering an accurate, non-invasive, inexpensive blood test to diagnose bowel cancer early.

The founding group comprises of business, research and healthcare professionals.

CanSense is combining trials, developing spectroscopy hardware and cutting-edge AI/ML software.

“ Prisma has enabled us to strengthen our plans, focus our technical efforts, refine our hiring schedule [...] in a way that supports our key business goals.

ADAM BRYANT, PhD, CEO

Adam understands early stage investing and the exacting requirements taking an IVD product to market. With a 20+ year career in Investment Banking, creating and leading dynamic and extremely successful global project teams.

Adam co-founded CanSense in 2018.

PROCESS FOR CANSENSE

Understand, aim, model:

- Wardley map the entire business
- Identify stakeholders and goals
- Make initial system/software design

Our design enabled greater context of business needs and for better decisions.

prisma.com | contact@prisma.com | 01865 575 135

Wood Centre for Innovation | Quarry Road | Oxford OX3 8SB

© Prisma Limited 2022

FULL QUOTE: ADAM

Prismaea made it really easy to involve them in our business. Their attitude and knowledge is impressive, and they integrated with our team perfectly. This allowed our expertise to take the forefront and for their knowledge to validate plans, link ideas and complement our experiences - and really provide benefit to our company.

Prismaea's breadth of experience across clinical trials, the MHRA and in scientific-led innovation - of what works, as well as pitfalls to avoid - has enabled us to strengthen our plans, focus our technical efforts, refine our hiring schedule, and decide which technical / cloud partners to engage more with in a way that supports our key business goals.

COMPANY: CANSENSE

Bowel (colorectal) cancer is the second most common cancer globally. It is the leading cause of cancer-related death in the Western world. Early diagnosis of bowel cancer significantly reduces mortality rate.

CanSense are delivering an accurate, non-invasive, inexpensive blood test to diagnose bowel cancer early - using a label-free assay and combining laser spectroscopy with advanced data analytics.

The development of a high throughput platform allows their diagnostic solution to be scalable. The platform is continuously improving through research use and large scale clinical studies.



MAPPING THE SPACE

Prismaea used **Wardley mapping** to understand the entire business - showing interactions, USP, commodity and outlier assumptions - as well as all stakeholder requirements.

ARCHITECTURE AND DESIGN

We presented a **full system design** encompassing all business, science and technical aspects as a straw-man - enabling planning, validation and impact analyses across the business.

prismaea.com | contact@prismaea.com | 01865 575 135

Wood Centre for Innovation | Quarry Road | Oxford OX3 8SB

© Prismaea Limited 2022